If you have checked your ASX share portfolio lately and winced – you're not alone.
Between global trade tensions, geopolitical uncertainty, and a sea of red on Wall Street, the share market has been on a rollercoaster ride that no one queued up for.
But here is one thing smart investors know: volatility is temporary, but quality compounds forever.
Right now, some of the best ASX shares are trading at big discounts. And if you've got a long-term mindset, this may be one of the better opportunities you'll get all year to buy future winners at a markdown.
Here are three ASX shares I believe are worth owning through the next decade – and maybe even longer.
Life360 Inc (ASX: 360)
Best known for its eponymous family safety app, Life360 is a technology company that has been growing its user base at lightning speed, with premium subscriber numbers soaring. Its strong recurring revenue base, significant addressable market, and brand stickiness make it a compelling long-term bet on the digital safety and location services market. The recent market selloff has pulled back its share price, but the business fundamentals are stronger than ever.
Goldman Sachs rates it as a buy with a $27.00 price target.
Lovisa Holdings Ltd (ASX: LOV)
Fast fashion, fast growth. Lovisa has built a global jewellery empire with a surprisingly simple formula: trend-focused, affordable accessories delivered at speed. The ASX share has cracked the code for international expansion, now operating in more than 40 countries and growing its store footprint rapidly. And while it shares have pulled back massively from their highs, the growth runway — especially in North America and Europe — remains enormous.
It is for this reason that Morgans has an add rating and $35.00 price target on the company's shares
Pro Medicus Ltd (ASX: PME)
When it comes to high-quality healthcare technology, Pro Medicus is in a league of its own. Its radiology imaging platform is used by some of the world's best hospitals, and long-term contracts provide incredible revenue visibility. The company has no debt, huge margins, and a habit of exceeding market expectations. While volatility can hit even the best stocks, this ASX share's long-term story — driven by global healthcare digitisation — looks as bright as ever.
Goldman Sachs believes this is the case and has a buy rating and $309.00 price target on its shares.
